Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 1 client • 12 examiners • 12 art units • 0 of 12 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Norton Rose Fulbright - UT Southwestern handles Biotechnology & Pharmaceuticals matters with 12 pending office actions and 109 career applications. Its resolved allowance rate is 84.0%, showing allowance in a substantial majority of resolved applications. The open-action inventory is material in the context of the recorded application portfolio, making active prosecution management important for this practice.
The average of 3.71 office actions per allowance indicates that allowed matters generally involve several examination exchanges. Practitioners can use the allowance rate to understand resolved outcomes and the action average to anticipate response work. The profile supports a prosecution approach that combines close docket monitoring with claim and amendment planning for biotechnology and pharmaceutical inventions.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (8%) |
| §103 only | 4 (33%) |
| §112 only | 1 (8%) |
| Multi-statute (no §101) | 6 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOYLAN, JAMES T | 1 | 63.3% | +10.8% |
| KELLEY, CHRISTOPHER S | 1 | 32.0% | +8.9% |
| MUHAMMAD, KEY | 1 | 64.7% | +22.8% |
| DAUNER, JOSEPH G | 1 | 57.0% | +35.3% |
| WESTON, ALYSSA G | 1 | 59.5% | +49.0% |
| MEJIAS, SAMANTHA LEE | 1 | 46.7% | +40.0% |
| MORGAN, BAILEY MICHELLE | 1 | 56.3% | +58.3% |
| KASAYAN, KATRIEL BARCELLANO | 1 | 25.0% | +0.0% |
| SHARIFF, MICHAEL ADAM | 1 | 79.7% | +24.4% |
| HUDSON, AMY ROSE | 1 | 74.8% | +11.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998037 | SYSTEMS AND METHODS FOR CHARACTERIZING A TUMOR MICROENVIRONMENT USING PATHOLOGICAL IMAGES | SHARIFF, MICHAEL ADAM | 46d overdue |
| 18014850 | TDP-43 BIOSENSOR CELL LINES | KASAYAN, KATRIEL BARCELLANO | 31d overdue |
| 18032760 | PROINFLAMMATORY PRODRUGS | MEJIAS, SAMANTHA LEE | 71d |
| 18697643 | OPTICAL ROTATOR SYSTEMS AND METHODS | MUHAMMAD, KEY | — |
| 18504868 | METHODS OF PREDICTING AND TREATING IMMUNOTHERAPY TOXICITY BASED ON IMMUNE CELL POPULATIONS | DAUNER, JOSEPH G | — |
| 18266712 | TAU BIOSENSOR CELL LINES | WESTON, ALYSSA G | — |
| 17905285 | METHOD FOR DIAGNOSIS AND/OR PROGNOSIS OF LIVER DISEASE PROGRESSION AND RISK OF HEPATOCELLULAR CARCINOMA AND DISCOVERY OF THERAPEUTIC COMPOUNDS AND TARGETS TO TREAT LIVER DISEASE AND CANCER | HUDSON, AMY ROSE | — |
| 17782402 | URINE ANALYSIS DEVICES AND METHODS FOR REAL TIME MONITORING OF KIDNEY FUNCTION | WESTFALL, SARAH ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998037 | SYSTEMS AND METHODS FOR CHARACTERIZING A TUMOR MICROENVIRONMENT USING PATHOLOGICAL IMAGES | SHARIFF, MICHAEL ADAM | 46d overdue |
| 18933931 | IMAGING SYSTEM AND METHOD TO CONVERT LATERAL SCANNING INTO AXIAL REMOTE FOCUSING | BOYLAN, JAMES T | 2d overdue |
| 18032760 | PROINFLAMMATORY PRODRUGS | MEJIAS, SAMANTHA LEE | 71d |
| 18697643 | OPTICAL ROTATOR SYSTEMS AND METHODS | MUHAMMAD, KEY | — |
| 18504868 | METHODS OF PREDICTING AND TREATING IMMUNOTHERAPY TOXICITY BASED ON IMMUNE CELL POPULATIONS | DAUNER, JOSEPH G | — |
| 18266712 | TAU BIOSENSOR CELL LINES | WESTON, ALYSSA G | — |
| 18042231 | COMBINATION IMMUNOTHERAPY METHODS FOR THE TREATMENT OF CANCER | MORGAN, BAILEY MICHELLE | — |
| 17905285 | METHOD FOR DIAGNOSIS AND/OR PROGNOSIS OF LIVER DISEASE PROGRESSION AND RISK OF HEPATOCELLULAR CARCINOMA AND DISCOVERY OF THERAPEUTIC COMPOUNDS AND TARGETS TO TREAT LIVER DISEASE AND CANCER | HUDSON, AMY ROSE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| University of Texas | 12 |
| Art Unit | Apps |
|---|---|
| 2486 | 1 |
| 2482 | 1 |
| 2872 | 1 |
| 1682 | 1 |
| 1633 | 1 |
| 1618 | 1 |
| 1645 | 1 |
| 1634 | 1 |
| 2672 | 1 |
| 1636 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18933931 | IMAGING SYSTEM AND METHOD TO CONVERT LATERAL SCANNING INTO AXIAL REMOTE FOCUSING | The Board Of Regents Of The University Of Texas System | BOYLAN, JAMES T | 2486 | §103Other | Final Rejection | 2d overdue | Pending | Oct 31, 2024 |
| 18833074 | DORSAL MEDULLA SURFACE TEXTURE AS AN IMAGING METRIC TO DISTINGUISH BETWEEN NEUROLOGICAL DISORDERS SYSTEMS AND METHODS | The Board Of Regents Of The University Of Texas System | KELLEY, CHRISTOPHER S | 2482 | §103 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18697643 | OPTICAL ROTATOR SYSTEMS AND METHODS | The Board Of Regents Of The University Of Texas System | MUHAMMAD, KEY | 2872 | §102§103§112 | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18504868 | METHODS OF PREDICTING AND TREATING IMMUNOTHERAPY TOXICITY BASED ON IMMUNE CELL POPULATIONS | The Board Of Regents Of The University Of Texas System | DAUNER, JOSEPH G | 1682 | §103§112 | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18266712 | TAU BIOSENSOR CELL LINES | The Board Of Regents Of The University Of Texas System | WESTON, ALYSSA G | 1633 | §102§103§112 | Non-Final OA | — | Pending | Jun 12, 2023 |
| 18032760 | PROINFLAMMATORY PRODRUGS | The Board Of Regents Of The University Of Texas System | MEJIAS, SAMANTHA LEE | 1618 | §102§103§112 | Non-Final OA | 71d | Pending | Apr 19, 2023 |
| 18042231 | COMBINATION IMMUNOTHERAPY METHODS FOR THE TREATMENT OF CANCER | The Board Of Regents Of The University Of Texas System | MORGAN, BAILEY MICHELLE | 1645 | §103 | Final Rejection | — | Pending | Feb 20, 2023 |
| 18014850 | TDP-43 BIOSENSOR CELL LINES | The Board Of Regents Of The University Of Texas System | KASAYAN, KATRIEL BARCELLANO | 1634 | §112 | Final Rejection | 31d overdue | Pending | Jan 06, 2023 |
| 17998037 | SYSTEMS AND METHODS FOR CHARACTERIZING A TUMOR MICROENVIRONMENT USING PATHOLOGICAL IMAGES | The Board Of Regents Of The University Of Texas System | SHARIFF, MICHAEL ADAM | 2672 | §103§112 | Final Rejection | 46d overdue | Pending | Nov 06, 2022 |
| 17905285 | METHOD FOR DIAGNOSIS AND/OR PROGNOSIS OF LIVER DISEASE PROGRESSION AND RISK OF HEPATOCELLULAR CARCINOMA AND DISCOVERY OF THERAPEUTIC COMPOUNDS AND TARGETS TO TREAT LIVER DISEASE AND CANCER | The Board Of Regents Of The University Of Texas System | HUDSON, AMY ROSE | 1636 | §101§103§112 | Non-Final OA | — | Pending | Aug 30, 2022 |
| 17782402 | URINE ANALYSIS DEVICES AND METHODS FOR REAL TIME MONITORING OF KIDNEY FUNCTION | The Board Of Regents Of The University Of Texas System | WESTFALL, SARAH ANN | 3791 | §102§112 | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17095179 | ARCHIVING RADIATION THERAPY RECORDS FOR TRANSMISSION AND REVIEW | The Board Of Regents Of The University Of Texas System | PORTER, RACHEL L | 3684 | §103 | Non-Final OA | 30d overdue | Pending | Nov 11, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial84.0% of resolved applications prosecuted by Norton Rose Fulbright - Ut Southwestern were allowed, across 109 applications in USPTO records.
3.71 office actions per allowed application on average.
12 pending office actions as of October 2026, for 1 client, before 12 examiners in 12 art units.
